Resume

• 1989

  Ph.D.

  •Synthesized critical sections of a high-mannose glycopeptide present on the surface glycoprotein

  gp120

  of HIV.\n•Extended the applications of pentenyl glycosides for the construction of large

  branched carbohydrates

  beta-mannosides and for the formation of beta-N linkages to peptides.

  Organic Chemistry

  Carbohydrates

• 1985

  LC-MS

  Biochemistry

  Inflammation

  Drug Design

  Drug Development

  HPLC

  Medicinal Chemistry

  GPCRs

  R&D

  Pharmaceutical Industry

  NMR

  Organic Chemistry

  Synthetic Organic Chemistry

  Drug Discovery

  Chemistry

  Organic Synthesis

  Science

  Higher Education

  Lifesciences

  Laboratory

  Merritt

  Specialties: Chemokine receptor antagonists

  medicinal lead discovery and optimization

  combinatorial synthesis

  GPCRs

  inflammation

  carbohydrates

  James

  Merritt

  Ligand Pharmaceuticals

  AAIPharma

  Pharmacopeia

  Duke University

  Kean University

  The College of New Jersey

  •Medicinal chemistry chairperson for discovery collaboration with Bristol Myers Squibb\n•Directed medicinal chemistry efforts for a CNS program\n•Supervised a group of Ph.D. and M.S. level chemists.\n•Managed/directed outsourced chemistry efforts with a group of chemists in India

  Ligand Pharmaceuticals

  Post-doctoral Research Associate

  Developed novel solid-phase route for synthesis of carbohydrates

  Duke University

  Chemist

  AAIPharma

  Adjunct Professor

  Taught Organic & General Chemistry Lectures and Laboratories

  The College of New Jersey

  Associate Professor

  Organic and Medicinal Chemistry\nNJ Center for Science Technology and Mathematics (NJCSTM)

  Kean University

  Senior Principal Scientist

  Medicinal Chemistry Project Leader\n•Managed drug discovery programs for various chemokine receptor antagonists\n•Discovered

  optimized and patented novel CXCR2 antagonists\n•CXCR2 antagonist advanced into human clinical trials \n•Discovered

  optimized and patented novel CCR1 antagonists\n•Advanced CCR1 antagonist into preclinical development\n•Worked closely with biologists and pharmacologists to facilitate advancement of promising compounds.\n•Medicinal chemistry chairperson for discovery collaboration with Bristol Myers Squibb\n•Medicinal chemistry project leader in discovery collaboration with Schering-Plough\n•Supervised groups of Ph.D.

  M.S. and B.S. level chemists.\n•Established and managed outsourced chemistry efforts with groups of chemists in China and India

  Pharmacopeia

  BS

  Chemistry